Candesartan in heart failure

(2447) Views  (455) Full article downloads

Authors: Toni L Ripley, Jennifer S Chonlahan, Robin E Germany

Published Date February 2006 Volume 2006:1(4) Pages 357 - 366

DOI: http://dx.doi.org/10.2147/CIA.S

Toni L Ripley¹, Jennifer S Chonlahan¹, Robin E Germany^2
1University of Oklahoma College of Pharmacy, ²University of Oklahoma College of Medicine, Oklahoma City, OK, USA

Abstract: Candesartan cilexetil is a nonpeptide selective blocker of the angiotensin II receptor sub-type 1. It is a prodrug that is converted to its active metabolite during its variable absorption. It is highly protein bound with a small volume of distribution and a nine-hour half-life. Candesartan is one of two angiotensin receptor blockers approved for use in heart failure. MEDLINE was searched using OVID and PubMed to evaluate the evidence for using candesartan in patients with heart failure. Pharmacologic and pharmacokinetic evaluations, as well as clinical trials, were selected and are presented in this review. Clinical evidence supports the indication for use in systolic heart failure. Results for use in patients with diastolic heart failure were non-significant. Candesartan was well tolerated in the trials, with hyperkalemia, renal dysfunction, and hypotension being the most common adverse events. Use of angiotensin receptor blockers with angiotensin-converting enzyme inhibitors needs further study; however, candesartan appears to provide added benefit in this setting. Candesartan is a safe and effective option for patients with systolic heart failure. Data regarding other angiotensin receptor blockers is underway.

Keywords: candesartan, heart failure, angiotensin receptor blocker